METHOD OF PREDICTING THE TUMOR RESPONSE TO DNA METHYLATION INHIBITORS
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F18%3A73591399" target="_blank" >RIV/61989592:15110/18:73591399 - isvavai.cz</a>
Result on the web
<a href="https://worldwide.espacenet.com/publicationDetails/biblio?II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20170201&CC=EP&NR=3122902A1&KC=A1" target="_blank" >https://worldwide.espacenet.com/publicationDetails/biblio?II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20170201&CC=EP&NR=3122902A1&KC=A1</a>
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
METHOD OF PREDICTING THE TUMOR RESPONSE TO DNA METHYLATION INHIBITORS
Original language description
The present invention provides a method for predicting the sensitivity of a patient suffering from a cancer disease to DNA methylation inhibitor therapy, which comprises determining in vitro in cancer cells taken from the patient and comparing with values for parent type of cells - the level of expression of at least one bromodomain containing gene, and/or - the level of expression of at least one bromodomain containing protein and/or - the mutations involving the non-synonymous change in amino acid sequence of at least one bromodomain containing gene and/or - the half maximal inhibitory concentration (IC 50 ) of a DNA methylation inhibitor and/or a histone demethylase inhibitor, wherein the increase in the half maximal inhibitory concentration of the DNA methylation inhibitor and/or the histone demethylase inhibitor signifies cross-resistance, and/or - the half maximal inhibitory concentration (IC 50 ) of a selective BET bromodomain inhibitor, wherein the decrease in the half maximal inhibitory concentration of the selective BET bromodomain inhibitor signifies sensitivity. The invention further provides a combination therapy of cancers using bromodomain inhibitors in combination with DNA methylation inhibitors.
Czech name
—
Czech description
—
Classification
Type
P - Patent
CEP classification
—
OECD FORD branch
10608 - Biochemistry and molecular biology
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2018
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Patent/design ID
EP 3122902 B1
Publisher
EPO_1 -
Publisher name
European Patent Office
Place of publication
Munich, The Hague, Berlin, Vienna, Brussels
Publication country
—
Date of acceptance
May 16, 2018
Owner name
Palacký University in Olomouc
Method of use
A - Výsledek využívá pouze poskytovatel
Usage type
A - K využití výsledku jiným subjektem je vždy nutné nabytí licence